Seminars in Radiation Oncology最新文献

Emerging Systemic Therapy Considerations for Pancreatic Cancer 胰腺癌新出现的全身治疗考虑

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.07.006

Kai-li Liang , Matthew Z. Guo , Neeha Zaidi

引用次数: 0

Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics 分子遗传学推动胰腺癌精准医疗

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.08.004

Maria Farooq , Michael J. Pishvaian

引用次数: 0

Intraoperative Radiation for Pancreatic Cancer 胰腺癌术中放射治疗

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.07.008

Ahmed Elguindy , Dukagjin Blakaj , John Grecula , Eric D. Miller

引用次数: 0

Adjuvant Radiation for Resected Pancreatic Cancer: Historical Review and Current State 胰腺癌切除术的辅助放疗：历史回顾与现状

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.07.009

John Starner , Yen-Ruh Wuu , Nicholas Hornstein , Karyn A. Goodman , Joseph M. Herman , Ross Abrams , Leila T. Tchelebi

引用次数: 0

Optimal Target Volume Delineation for Pancreatic Cancer: Triangulating What Should be Targeted 胰腺癌的最佳靶体积描绘：三角定位应该是什么

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.08.003

Amol Narang

引用次数: 0

Beyond Opioids in Pancreatic Cancer: Palliative Radiotherapy and Celiac Plexus Radiosurgery 胰腺癌中的阿片类药物：姑息性放疗和腹腔丛放射手术

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.07.005

Marcin Miszczyk , Ross A. Abrams , Yaacov R. Lawrence

{"title":"Beyond Opioids in Pancreatic Cancer: Palliative Radiotherapy and Celiac Plexus Radiosurgery","authors":"Marcin Miszczyk , Ross A. Abrams , Yaacov R. Lawrence","doi":"10.1016/j.semradonc.2025.07.005","DOIUrl":"10.1016/j.semradonc.2025.07.005","url":null,"abstract":"<div><div>This review examines established and evolving approaches for radiation therapy as a palliative treatment modality in patients with pancreatic cancer within the context of effective patient-provider communication and early palliative care team based management. At presentation most patients with pancreatic cancer have advanced disease and a limited life expectancy. Typically, they suffer from multiple disease-related symptoms. Systemic therapies have limited palliative efficacy against symptoms associated with local disease. This is in contrast to radiation therapy, which appears efficient in achieving local symptom control. In addition to more conventional tumour-targeting stereotactic body radiation therapy (SBRT), and short-course conventional radiotherapy, a recent clinical trial demonstrated the effectiveness of a new approach - celiac plexus radiosurgery. In this article, we evaluate and compare the effectiveness of these treatment methods, demonstrating the important, yet underappreciated, role that hypofractionated radiation therapy has within the multidisciplinary management of patients with pancreatic cancer, including those with metastatic disease.</div></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"35 4","pages":"Pages 546-555"},"PeriodicalIF":3.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality and Quantity: Dual Benefits of Ablative Radiation in Oligometastatic Pancreatic Cancer 质与量：消融放疗治疗少转移性胰腺癌的双重益处

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.07.004

Todd A. Aguilera , Ahmed M. Elamir , Ethan B. Ludmir

{"title":"Quality and Quantity: Dual Benefits of Ablative Radiation in Oligometastatic Pancreatic Cancer","authors":"Todd A. Aguilera , Ahmed M. Elamir , Ethan B. Ludmir","doi":"10.1016/j.semradonc.2025.07.004","DOIUrl":"10.1016/j.semradonc.2025.07.004","url":null,"abstract":"<div><div>Oligometastatic pancreatic cancer (OPanc) poses significant opportunities in management, as increasingly metastases can be safely and effectively targeted with local therapy. We review the existing literature on SABR for OPanc, highlighting its potential benefits and limitations with an aim to define the trajectory of opportunity. SABR may offer a meaningful benefit to patients with OPanc, improving quality of life by enabling breaks from systemic therapy while potentially enhancing quantity of life or survival. Patient selection and clearly defined goals will be critical to demonstrate the value of this approach, and well powered prospective studies may be key. The most intriguing aspect of this discussion is the potential for SABR to enhance antitumor immunity that may play a role in prolonged minimal residual disease that can be achieved in some patients. This can translate to improved quality of life by reducing the need for systemic therapy. This approach may offer a novel solution to the treatment challenges associated with OPanc. Further research is needed to confirm the hypotheses and establish the definitive role of SABR in OPanc treatment.</div></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"35 4","pages":"Pages 538-545"},"PeriodicalIF":3.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Moving Beyond the Standard Pancreatectomy for Pancreatic Adenocarcinoma 超越标准胰腺切除术治疗胰腺腺癌

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.08.001

Madeleine D. Hunter , Nupur Shridhar , Kate Mlouk , Brian Kaplan , Greg D. Sacks , Christopher L. Wolfgang , Michael D. Kluger

{"title":"Moving Beyond the Standard Pancreatectomy for Pancreatic Adenocarcinoma","authors":"Madeleine D. Hunter , Nupur Shridhar , Kate Mlouk , Brian Kaplan , Greg D. Sacks , Christopher L. Wolfgang , Michael D. Kluger","doi":"10.1016/j.semradonc.2025.08.001","DOIUrl":"10.1016/j.semradonc.2025.08.001","url":null,"abstract":"<div><div>This manuscript describes the evolution in the operative management of pancreatic cancer. Early attempts at pancreatic resection were met with daunting peri‑operative outcomes but were fine-tuned to yield today’s established pancreatic resections. Advances in medical therapy, including neo-adjuvant therapy for borderline resectable pancreatic cancers and refined adjuvant regimens, have improved oncologic outcomes and are allowing surgeons to move beyond current anatomic distinctions of resectability. Venous, hepatic artery and celiac axis resection during pancreatectomy are now common vascular operations at specialty centers which have been associated with favorable oncologic outcomes. Recent efforts are addressing locally advanced pancreatic cancer with superior mesenteric artery and/or multivessel involvement using either arterial divestment or arterial resection and reconstruction. An additional consideration in the treatment of pancreatic cancer is the benefit and risks of neoadjuvant radiation in locally advanced cases which has been avoided thus far given concerns regarding the effect of radiation on the vasculature. Therefore, with these improvements in peri‑operative therapy and robust preoperative planning often with the aid of vascular and microvascular surgeons, several centers have been exploring new frontiers in the operative management of locally advanced pancreatic adenocarcinoma.</div></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"35 4","pages":"Pages 598-607"},"PeriodicalIF":3.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Applications of Quantitative Imaging and Artificial Intelligence for Pancreatic Cance 胰腺癌定量成像与人工智能的临床应用

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.07.003

Yeseul Kim , David Martinus , Taydan T. Tran , Michael K. Rooney , Anya Pant , Rance B. Tino , Eugene J. Koay

{"title":"Clinical Applications of Quantitative Imaging and Artificial Intelligence for Pancreatic Cance","authors":"Yeseul Kim , David Martinus , Taydan T. Tran , Michael K. Rooney , Anya Pant , Rance B. Tino , Eugene J. Koay","doi":"10.1016/j.semradonc.2025.07.003","DOIUrl":"10.1016/j.semradonc.2025.07.003","url":null,"abstract":"<div><div>Pancreatic cancer remains as a leading cause of cancer death in the United States due to the disease’s deadly combination of evasiveness to detection, aggressive biology, and resistance to treatment. Quantitative imaging and artificial intelligence (AI) methods are emerging as promising and innovative techniques to combat the extensive challenges facing the clinic in the diagnosis and treatment of pancreatic ductal adenocarcinoma. These methods extract data from the fabric of clinical images that allow for earlier diagnosis, improved prognostication, automation of treatment planning, and increased reliability for response assessment. This review examines quantitative imaging techniques from 2013 to 2025 and summarizes them into three parts: differential diagnosis for pancreatic disease, grading and staging of pancreatic tumors, and treatment response assessment and prognosis prediction. We outline key challenges specific to pancreatic cancer and potential mitigations for future direction. We also highlight developing areas such as MRI-guided adaptive radiotherapy, automated target delineation, and integrated radiomic-omics tools that may help incorporate quantitative imaging into routine care of pancreatic cancer. Altogether, the current investigation suggests that quantitative imaging will become an integral tool for this disease across the oncologic journey of a patient.</div></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"35 4","pages":"Pages 556-582"},"PeriodicalIF":3.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma 胰腺导管腺癌术前治疗的当代进展、证据和考虑

IF 3.2 3区医学

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI: 10.1016/j.semradonc.2025.07.007

Alexander D. Sherry MD , Alexandra K. Bennett MD , Ryan M. Carr MD, PhD , Mark J. Truty MD, MS , Krishan R. Jethwa MD

{"title":"Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma","authors":"Alexander D. Sherry MD , Alexandra K. Bennett MD , Ryan M. Carr MD, PhD , Mark J. Truty MD, MS , Krishan R. Jethwa MD","doi":"10.1016/j.semradonc.2025.07.007","DOIUrl":"10.1016/j.semradonc.2025.07.007","url":null,"abstract":"<div><div>Localized pancreatic ductal adenocarcinoma (PDAC) has been historically associated with poor disease control outcomes following surgical resection alone. Due to the high risk of occult locoregional and distant metastatic disease and anatomic tumor complexity limiting margin-negative resectability, preoperative therapy has emerged as an appealing strategy for many patients across the spectrum of localized PDAC. Here, we critically review the context, evidence, and controversies regarding preoperative therapy for PDAC. We first discuss the natural history of PDAC, patterns of spread and postoperative therapy. We then consider current issues of resectability, patient selection, therapy sequencing, and specifically the role of radiation therapy, including chemoradiation and stereotactic body radiation therapy, in the preoperative paradigm respectively. We conclude by discussing ongoing trials attempting to provide further insights and illuminating the path towards the improvement of outcomes in this patient population.</div></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"35 4","pages":"Pages 495-509"},"PeriodicalIF":3.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0